Effectiveness of first-line antiretroviral therapy in the IPEC cohort, Rio de Janeiro, Brazil

Table 1 Baseline socio-demographic, behavioral, clinical and structural characteristics at first-line antiretroviral therapy (ART) initiation (IPEC Clinical Cohort, 2000 to 2010)

Total		1311
Age
	Mean (SD)	37.1 (9.9)
	< 30	355 (27.1)
	30-39	446 (34.0)
	≥ 40	510 (38.9)
Race
	Non-white	621 (47.4)
	White	690 (52.6)
Gender/Risk category ^a
	Women	432 (33.0)
	Heterosexual men	327 (24.9)
	MSM	423 (32.3)
	IDU/Other	129 (9.8)
Years of formal education
	< 4	277 (21.1)
	4-8	380 (29.0)
	> 8	654 (49.9)
Years since HIV + test
	<= 3	836 (63.8)
	> 3	475 (36.2)
Pre-treatment CD4 count/μL ^b
	Mean (SD)	233 (184)
	<= 200	494 (37.7)
	201-350	392 (29.9)
	> 350	208 (15.9)
	Missing	217 (16.6)
Pre-treatment HIV viral load copies/mL ^c
	<= 100000	532 (40.6)
	> 100000	466 (35.5)
	Missing	313 (23.9)
Concurrent AIDS defining illness ^d
	No	1013 (77.3)
	Yes	298 (22.7)
Hepatitis B/C co-infection ^e
	No	1270 (96.9)
	Yes	41 (3.1)
ART regimen ^f
	PI-based	324 (24.7)
	NNRTI-based	987 (75.3)
Calendar year of ART initiation
	2000-2004	392 (29.9)
	2005-2009	919 (70.1)
Started ART in clinical trial
	No	856 (65.3)
	Yes	455 (34.7)

SD: standard deviation, HIV: human immunodeficiency virus, PI: protease inhibitor, NNRTI: non-nucleoside reverse transcriptase inhibitor.
^aGender and reported mode of HIV exposure were categorized jointly into women, men who have sex with men (MSM), heterosexual men, and injection drug users (IDU, men and women) and other reported modes of HIV exposure (men and women). Individuals reporting both injection drug use and other modes of HIV exposure were categorized as IDU.
^bMeasurement closest to the date of start of ART up to 30 days after.
^cMeasurement closest to the date of start of ART up to 7 days after.
^dDefined as the presence of any Centers for Disease Control and Prevention (CDC) 1993 disease from 90 days prior to up to 30 days after start of ART.
^eChronic Hepatitis B infection was defined as persistence of a positive HBsAg for more than six months without a subsequent negative HBsAg; chronic Hepatitis C infection was defined as a confirmed positive anti-HCV detected at least six months from the first test.
^fPatients starting Integrase inhibitor-based regimens were too few and thus excluded (7 individuals with start of ART in 2010).
Unless otherwise stated, number (percentages) are shown.

ISSN: 1742-6405